Prasugrel Hydrochloride (LY 640315 Hydrochloride) is a piperazine derivative and pletelet aggregation inhibitor that is used to prevent thrombosis in patients with acute coronary syndrome.

Prasugrel significantly inhibits arterio-venous (AV) shunt and electrically induced arterial thrombosis in single dose ranges of 0.3 to 3 mg/kg and of 0.3 and 1 mg/kg/day for multiple doses. These doses are similar to doses with inhibition of platelet activation via P2Y12 receptors, suggesting that the protective effects of prasugrel in these cerebral infarction and peripheral arterial occlusive disease models reflect P2Y12 inhibitions on platelets by prasugrel's active metabolite. Prasugrel also significantly prevents progression of peripheral vascular lesions[1].